Sanofi to Explore Counterbid for Actelion Amid J&J Talks


Sanofi is considering a counterbid for Actelion Ltd., potentially challenging a move by U.S. health-care giant Johnson & Johnson to acquire the Swiss biotechnology firm, people familiar with the matter said. The French drugmaker is working with advisers as it weighs its options, said the people, who asked not to be identified because the deliberations are private.



from Biotech News